Both microglia and macrophages have been increasingly recognized for their important roles in brain function. Under physiological conditions, microglia are exquisite sensors of changes in their microenvironments, detecting infection or damage and responding by migrating, proliferating, phagocytosing or producing cytokines and neurotrophins to protect, defend and maintain a homeostatic environment 1 (Fig. 1) . Such responses are also observed in a wide range of neurodegenerative conditions (Fig. 1) as well as in acute conditions such as stroke; however, in these instances, the microglial response may become dysregulated and chronic 2 . In certain conditions, monocyte-derived macrophages that are usually restricted to the periphery are thought to enter the brain, where they have been shown to be capable of assuming a microglia-like phenotype 3, 4 . Several factors have pushed microglia into the forefront of neuroscience research in recent years. These include the growing appreciation of the role of these cells in the development of neurological conditions, particularly dementia (an escalating societal and economic problem in Western society with an urgent need for therapeutics), and the findings of recent human genetic studies (and particularly of genome-wide association studies and whole-genome sequencing studies) that have highlighted a clear genetic link between dementia and inflammation [5] [6] [7] . models directly from human monocytes 15, 16 , and several cell biology companies have been established that specialize in the production of such cells. However, owing to the rarity of many of the genetic risk factors associated with neurodegenerative diseases, cells from these sources are unlikely to express the single-nucleotide polymorphisms or mutations that would enable targeted studies of these diseases. These risk factors can of course be introduced by new genome-editing technologies; however, to study the mutations in the context of disease, it is necessary to acquire cells directly from a patient.
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To address these concerns, recent advances in induced pluripotent stem cell (iPSC) methodologies that were initially developed to generate primitive and definitive haematopoietic cells and neurons 17, 18 are now being applied to the production of macrophages and microglia. The advantages of this approach include the ability to produce large numbers of human-derived cells with an adult phenotype, which is very difficult to obtain through traditional methods, and the provision of a source of cells expressing particular genetic mutations linked to disease, allowing in depth disease-relevant study of pathological mechanisms. This is especially advantageous when the number of patients expressing these gene mutations is very rare, as is the case for variants in genes encoding receptors, including mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2), that are linked to increased risk of developing late onset Alzheimer disease 5, 7 . These advances may enable future production of 'disease in a dish' models, which may allow us to better understand the consequences of genetic predisposition to dementias and other chronic neurological diseases in which microglia are thought to play a role. The sophistication of these models can be altered depending on the users' needs. Cells can be derived in isolation, or new culturing techniques, including organoid development, can be utilized to allow users to introduce microglia or microglial precursors into 3D tissues of neurons, astrocytes and oligodendrocytes (all with controlled phenotypes) to investigate cell autonomous and non-cell autonomous responses. These cells can
In addition, the well-established role of neuroinflammation in multiple sclerosis 8 and increasing evidence for its role in other neurodegenerative diseases, including Parkinson disease, Alzheimer disease and amyotrophic lateral sclerosis [9] [10] [11] , have helped to drive an increasing focus on microglia.
The lack of successful disease-modifying therapeutic developments in neurological diseases has brought into question the capacity of animal models to recapitulate the human condition 12, 13 . This, coupled with a growing opposition in Western society to the use of animals in research because of ethical and welfare concerns 14 , has led to the search for better humanized models of neurological function and disease. The use of primary human tissue provides one possible solution; however, this material is often derived from contentious sources, including fetal tissues, that also raise ethical concerns. In addition, although primary tissue is highly informative and vital for ongoing research, issues including post-mortem artefacts, the influence of underlying diseases (such as epilepsy) present in the individuals from whom the tissue is derived and the obvious difficulties in obtaining sufficient study material invalidate this as a source of material for long-term mechanistic studies of the early physiological changes that occur in neurological diseases.
These caveats have led to the development of approaches for the longterm culture of human cells. These have included the generation of microglia-like The schematic image illustrates some of the physiological functions of microglia that should be considered when using induced pluripotent stem cells as models of these cells. Microglia contribute to healthy nervous system physiology in several ways. They provide cues and remove inappropriate synapses during development, and they secrete neurotrophins and cytokines to support and maintain neural networks in the mature nervous system 42 . In addition, they rapidly sense ATP signalling via receptors such as P2Y purinoceptor 12 (P2Y12) 37, 38, 50 and migrate to areas of damage, where they proliferate and phagocytose apoptotic cells and any other damaged tissue to aid repair. Indeed, activation of microglia following CNS damage or disease induces a respiratory burst, which is necessary for an efficient innate immune response 38, 50 . Recent research has focused on the role of lipid signalling in microglia in neurological diseases, including Alzheimer disease. Such signalling is mediated by putative membrane-associated receptors, including triggering receptor expressed on myeloid cells 2 (TREM2), and mutations in TREM2 are genetic risk factors for Alzheimer disease 7 . Microglia also influence nervous system pathology in a number of disorders. They attack the myelin sheath of oligodendrocytes and Schwann cells, phagocytose myelin and attempt repair in multiple sclerosi,s and become reactive in white matter diseases such as leukodystrophies. Microglia migrate to and surround amyloid-β (Aβ) plaques in Alzheimer disease in an attempt either to phagocytose this aberrant protein or to corral and contain it to prevent neuronal damage. Microglia also become reactive in Huntington disease, dementia with Lewy bodies, Parkinson disease and Creutzfeldt-Jakob disease. In the ageing brain 7, 9, 10 , microglia appear dystrophic and become reactive, senescent and dysfunctional. In addition, their numbers are altered during ageing, decreasing in some areas of the brain and increasing in others (reviewed in REF.
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also be used to inform us of changes in the physiology of human microglia in the healthy nervous system during development and in genetic-associated diseases.
In this article we discuss the properties of microglia generated from iPSCs and consider the advantages and caveats of such models. To provide context to the history iPSC-derived microglia methodologies, we also briefly discuss the generation of iPSCderived macrophages.
Protocols and phenotypes
Several methods for the generation of iPSCderived microglia-like or macrophage-like cells from both human and rodent tissues have been published in the past 5 years (TablE 1) . These methods have allowed large numbers of cells to be produced and, in general, the phenotype of these cells has been described as being similar to either that of peripheral blood monocyte (PBM)-derived macrophages or that of tissue-resident macrophages and CNS-localized microglia. To date, all published protocols follow a similar path, which is based largely on cellular ontogeny. Donor cells are initially de-differentiated to produce iPSCs. These cells are then supplemented with growth factors associated with mesodermal specification, leading to the development of haemangioblasts and primitive haematopoietic progenitors, and this is followed by continued maturation along the myeloid lineage with further growth factor cocktails.
Several established protocols can produce microglia-like cells from human monocytes. However, the use of monocytederived microglia as a human model of CNS microglia remains contentious because of the differences in the proposed origins of CNS microglia from those of peripheral macrophages in vivo. Microglia are thought to be erythromyeloid progenitor (EMP)-derived, arising from the yolk-sac 19, 20 , whereas PBM-derived macrophages arise from circulating bone marrow-derived cells 21 . However, tissue-resident macrophages, including the Langerhans cells of the skin, alveolar macrophages of the lung and Kupffer cells of the liver 22 , are also derived from EMPs. These cells therefore do not have a monocytic progenitor and are maintained independently of the bone marrow, like microglia 19, 23, 24 . Furthermore, it has been shown that microglia and tissue-resident macrophages, but not PBM-derived macrophages, are derived from precursors whose development depends on transcription factor PU.1 and runt-related transcription factor 1 (RUNX1) but does not require the transcriptional activator MYB, indicating generated cells with phenotypes that resembled those of anti-inflammatory, regenerative 'M2-type' macrophages, including long filopodia, large intracellular vacuoles and expression of classical macrophage markers such as CD45 (also known as PTPRC), CD14, CD163 and CD86 (REF.
34
). These cells were also able to phagocytose latex beads and produce a number of cytokines in response to lipopolysaccharide, including tumour necrosis factor (TNF), monocyte chemoattractant protein 1 (MCP1; also known as CCL2), IL-6, IL-8 and IL-10 (REF.
). The ability to secrete IL-6 does, however, suggest that these cells consisted of somewhat mixed phenotypes, as this cytokine has been found to be secreted by inflammatory 'M1-type' macrophages and M2-type macrophages 35 . The high level of TNF secretion by iPSC-derived macrophages is also similar to that seen from PBM-derived M1-type macrophages 34 . One possibility, which should be explored, is that there may be an influence of priming on these findings, that is, pre-exposure to a stimulus, such as serum factors in undefined media compositions, may convert the cells into an alerted, activated state, as described by the M1-type and/or M2-type classification. It may therefore be necessary to mature the cells for longer in culture in order to ensure that they are in a more downregulated state, similar to that found in vivo.
Microglia or macrophages?
The variations in protocol and phenotype reported by the studies described above raise an important question: what defines an iPSCderived microglial cell and separates this from an iPSC-derived tissue-resident macrophage or monocyte-derived macrophage?
Recent transcriptomic studies of the differences between human iPSC-derived microglia and PBM-derived macrophages have proposed that microglia express the purinergic receptor P2Y12 and transmembrane protein 119 (TMEM119) 27, 28 , whereas peripheral PBM-derived macrophages do not 36 . Similarly, two recent studies also used transcriptomics to separate iPSC-derived microglia from other myeloid cells including dendritic cells, monocytes and macrophages 29, 30 . Calcium responses to ADP, which occur via P2Y12 stimulation, are evoked in iPSC-derived microglia but not in PBM-derived macrophages 28 . Other microglialspecific markers that have been shown to be expressed on human iPSC-derived microglia but not PBM-derived macrophages include ionized calcium-binding adapter molecule 1 (IBA1; also known as AIF1), integrin-αM different embryonic sources of these cells 19, 20, 25, 26 . Such discoveries have enabled researchers to refine iPSC-derived models to generate the cell-specific progenitors required for the development of true microglia-like cells. This allows for more phenotypically accurate studies that are potentially more translatable to in vivo conditions.
There is considerable debate in the literature about what cell phenotype certain iPSC-based microglial differentiation protocols actually produce. Recent advances in iPSC methodologies have found that a microglia-like phenotype can be induced by incubation of human iPSC-derived microglial and/or macrophage progenitors with various combinations of factors, including high levels of macrophage colony-stimulating factor 1 (CSF1) and interleukin-34 (IL-34) 27 ; IL-34 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 28 ; IL-3, IL-34 and GM-CSF 29 ; and IL-34, CSF1, transforming growth factor-β1 (TGFβ1), CX 3 C-chemokine ligand 1 (CX 3 CL1, also known as fractalkine) and CD200 (REF.
30
).
These protocols are able to generate cells that exhibit similar gene expression patterns to those of human primary microglia 28, 30 , express known microglial markers [27] [28] [29] [30] , perform microglial functions (including phagocytosis and secretion of cytokines) [27] [28] [29] [30] and respond to ADP or ATP via P2Y purinoceptor 12 (P2Y12) to produce intracellular calcium transients 28, 30 . Despite the phenotypic similarities between these iPSC-derived cells and endogenous microglia, the laboratories responsible for their production and others have questioned the simplicity of such models and have provided evidence that more complex culture conditions are necessary for the generation of more authentic models of microglia [29] [30] [31] [32] . Indeed, some prescribe the use of neuronal co-cultures to further enhance the microglial signature -that is, the gene expression, cytokine release in response to stimulants, phenotypic responses to exogenous or endo genous insults and cellular morpho logy -of their generated cells 27, [30] [31] [32] . Although several of the recently published protocols provide strong phenotypic evidence for the production of microglia-like cells, it is clear that there is not yet a definitive method for the production of a completely satisfactory microglial phenotype from iPSCs and that such a protocol is a work in progress.
The protocols described above differ from those used for the production of macrophages from human iPSCs, in which CSF1 and IL-3 have been used 33, 34 . In the presence of CSF1 alone, human iPSCs (ITGAM, also known as CD11b), integrin-αX (ITGAX, also known as CD11c) and CX 3 Cchemokine receptor 1 (CX 3 CR1) 28 . However, further study of these putative markers is required, as the expression levels of receptors are likely to be affected by the particular cocktail of growth factors or cytokines used. Microglia are capable of expressing a large repertoire of receptors 37, 38 that could influence their phenotype. However, several receptors expressed on human adult microglia, including P2Y12, CD64 (also known as FCγR1A) and tyrosine-protein kinase MER (MERTK), can become downregulated in microglia upon activation 39 . Therefore, none of these proteins in isolation can be used as a reliable marker for microglia derived from iPSC cells.
There are also subtle points of overlap between the phenotypes of microglia and those of tissue-resident macrophages, which depend on their level of activation (and thus overall gene and protein expression). Human microglia express the genes encoding complement C1q subcomponent subunit A (C1QA), CSF1 receptor (CSF1R) and CD34, as do other tissue-resident macrophages. Similarly, TAM-related genes such as those encoding MERTK, vitamin K-dependent protein S (PROS1) and growth arrest-pecific protein 6 (GAS6), which are expressed on human macrophages, are also expressed in human microglia 23 . Several genes regarded as providing a specific signature for rodent microglia were recently identified, including the genes encoding MERTK, G proteincoupled receptor 34 (GPR43), PROS1, C1QA, GAS6 and P2Y12 (REF.
23
). These genes were also found to be expressed in human iPSC-derived microglia that were co-cultured with human iPSC-derived cortical neurons or astrocytes 29, 31 and to differ from the genes expressed by blood-derived monocytes. However, the expression of some of these genes in other human tissue-resident macrophages does suggest that a microglialspecific signature for human cells is yet to be fully defined, and temporal changes in expression levels and an environmentspecific context must be taken into account 32 . As outlined above, transcriptomic studies that have compared mouse iPSC-derived microglia and macrophages have been used both to indicate the genes and proteins that may be important to consider when investigating mouse models of disease and to produce a possible genetic signature that is relevant for human microglia 23 . In addition, a recent study that compared gene expression in tissue-resected primary human microglia with that of isolated primary mouse microglia has led to the most comprehensive genetic microglial signature to date 40 . The authors generated a comprehensive picture of the transcriptomic and epigenetic landscapes of the primary isolated microglia to provide a detailed overview of human microglial identity. Interestingly, the authors found that there was extensive downregulation of microglia-specific genes when the cells were placed in a tissue culture environment, albeit using undefined serum-containing medium. The identification of such downregulation is a substantial caveat when trying to develop iPSC-derived microglia in vitro and lends further support to the importance of the environmental context that these cells are matured in 32 .
The type of information provided by transcriptomic studies enables fine-tuning of iPSC microglia methodologies to provide a more realistic phenotype. However, it will be imperative that, in the future, such comparisons are attempted with fully adult human microglia. Studies that use microglia resected from children have so far provided unparalleled data on primary human The table provides a brief overview of the current published methods of early induced pluripotent stem cell (iPSC) myeloid cell generation and subsequent techniques for the establishment of iPSC-derived macrophages and microglia. Please refer to the citations within for full comprehensive methodologies. Aβ, amyloid-β; bFGF, basic fibroblast growth factor (also known as FGF2); BMP4, bone morphogenetic protein 4; C1QA , complement C1q subcomponent subunit A ; CD16, also known as FCγR3; CD29, also known as ITGB1; CD39, also known as NTPDase 1; CD43, also known as SPN; CD49d, also known as ITGA4; CD115, also known as CSF1R; CX 3 CL1, CX 3 C-chemokine ligand 1; CX 3 CR1, CX 3 C-chemokine receptor 1; DKK1, dickkopf-related protein 1; ESC, embryonic stem cell; FGF2, fibroblast growth factor 2; FLT3L , FMS-related tyrosine kinase 3 ligand; GAS6, growth arrest-specific protein 6; GM-CSF, granulocyte-macrophage colonystimulating factor ; GPR34, probable G protein-coupled receptor 34; GSK3, glycogen synthase kinase 3; hiMacs, human iPSC-derived primitive macrophages; hiMicros, human iPSC-derived microglia-like cells; HL A , human leukocyte antigen; IBA1, ionized calcium-binding adapter molecule 1; IFNγ, interferon-γ; IFNγR , IFNγ receptor ; IL , interleukin; ITGAM, integrin-αM; ITGAX, integrin-αX; ITGB5, integrin-β5; LPS, lipopolysaccharide; MERTK , tyrosine-protein kinase MER; MHC, major histocompatibility complex; P2Y12, P2Y purinoceptor 12; PBMC, peripheral blood mononuclear cell; PROS1, vitamin K-dependent protein S; PU.1, transcription factor PU.1; RI, ROCK inhibitor ; ROS, reactive oxygen species; SCF, stem cell factor ; TGFβ1, transforming growth factor-β1; TGFβR1, TGFβ receptor type 1; THPO, thrombopoietin; TMEM119, transmembrane protein 119; TREM2, triggering receptor expressed on myeloid cells 2; VEGF, vascular endothelial growth factor.
a If both murine and human protocols are described, methodologies and derived cell phenotypes are described for the human protocol. NATure reviewS | NeuRoSCIeNCe P r o g r e s s microglial identity 40 . However, transcriptomic data from microglia derived from aged individuals, however small the cohort, may provide further information on temporal genetic changes, which may be more relevant to the study of disorders of old age.
Many phenotypic changes are known to occur in microglia with age. Broadly speaking, early postnatal microglia focus on synaptic pruning 41 and the refinement of CNS connectivity, whereas adult microglia exhibit a surveillant phenotype 42 . How then do the new iPSC-derived microglia compare with these differing microglia phenotypes? To date, only one study has directly compared iPSCderived microglia with both fetal and adult human microglia. This study used wholetranscriptome differential gene expression analysis to reveal increased expression of nearly 2,000 genes in iPSC microglia when compared with fetal microglia and just over 1,000 genes when compared with adult microglia. Furthermore, enrichment analysis provided an insight into how iPSC-derived microglia compare with fetal and adult microglia 30 . Three independent studies 23, 43, 44 appeared to show a strong similarity in the differences in gene expression levels observed between iPSC-derived microglia and primary human microglia. However, the age of the primary microglia was not reported 28 . Thus, further analysis of the published protocols is required to gauge how comparable the iPSCderived cells are with early or late primary microglia. This will not be an easy task owing to the limited availability of primary cell material; however, putting more emphasis on comparing these models with primary microglia rather than other myeloid cells should be a priority.
As shown above, several iPSC protocols produce good models of macrophage-like cells. The involvement of peripheral cellular dysfunction in diseases such as Alzheimer disease should not be ignored [45] [46] [47] , and thus it is likely that these cells can be used to inform us of the contributions of peripheral changes that can influence central disease. In addition, macrophages derived from the cells of human patients will express the variants implicated in disease, as will their central 'cousins' , the microglial cells. It is critical that both cell types are investigated with regard to disease, as their responses may be different 48 , and it may be advantageous to target one over the other when considering future therapeutic interventions.
In addition to molecular markers, morphological phenotypes are often used to define microglia versus macrophages. However, although it is true that surveillant microglia in the brain exhibit a highly ramified, motile phenotype compared with more bipolar phenotypes observed in macrophage cultures, this rapidly changes upon activation and is therefore not a particularly robust marker to distinguish a microglial cell from a macrophage. We would suggest that one morphological marker of a microglial phenotype is that of domain sensitivity and contact inhibition (Fig. 2) . Surveillant microglia very rarely touch each other in vivo or in vitro, and only when in an activated state do the cells display noncontact inhibition 49 ( Fig. 2) . Furthermore, human macrophages (particularly regulatory macrophages, which are akin to human surveillant microglia) in vitro do not display 
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• Escherichia coli [27] [28] [29] [30] [31] [32] . More comprehensive phenotype checking consists of RNA sequencing (RNA-seq) analysis of the iPSC-derived cells [28] [29] [30] . Comparative analyses of the cells' transcriptomic signatures to those recorded from primary microglia data sources will be important to improve the capacity of iPSC-derived microglia to model their endogenous counterparts. The ability of the cells to generate calcium transients and respiratory bursts in response to stimuli is also a fundamental microglial trait that should be present [28] [29] [30] . Integration into iPSC-derived organoids or other tissue sources enables researchers to critically assess microglial morphology 27, 29, 30, 32 . Contact inhibition, including tiling in vitro, is another classical microglial phenotype that should also be assessed 49 . CX 3 CR1, CX 3 C-chemokine receptor 1; F/F o , change in observed fluorescence; HL A , human leukocyte antigen; IBA1, ionized calcium-binding adapter molecule 1; ICC, immunocytochemistry ; ITGAM, integrin-αM; MHC, major histocompatibility complex; P2Y12, P2Y purinoceptor 12; PU.1, transcription factor PU.1; ROS, reactive oxygen species; TMEM119, transmembrane protein 119. contact inhibition 50, 51 . We therefore argue that several markers, including genes, proteins and morphology, need to be considered when defining a microglial cell and that no single marker will be sufficiently robust.
Culture types
Many recent studies of human iPSC-derived microglia have tended to focus on 2D cultures. This approach has both advantages and disadvantages for the user. For example, it is possible to study a cell type without the interference of signals from other cell types; however, the user is likely to be losing vital information from non-cell autonomous signalling. Therefore, many protocols are now focusing on the development of more complex systems, through the introduction of iPSCderived microglia progenitors to in vivo tissue models or to co-cultures, in a drive to produce cells that are more like microglia 27, [29] [30] [31] [32] . Co-culturing iPSC-derived microglia with neurons seems to produce microglialike cells with ramifications similar to those present in vivo 27, 31, 32 , although a ramified motile morphology has also been observed in monocultures 27, 28, 30 . In these cultures, there also appears to be a need for the CSF1R ligand IL-34, as well as low levels of GM-CSF or CSF1, to be provided in order to maintain microglial survival. This is not unexpected, given that the signals from neurons and other glia in the brain have a major influence on the survival and function of microglia and the genes and proteins that they express.
If one is to attempt a more complex culture approach, it seems likely that it is important to include as many different brain cell types as possible. Indeed, the assumption that culturing iPSC-derived microglia solely with neurons goes some way to approaching a more realistic microglial phenotype may be somewhat naive, given the complexity of brain structure and organization. Furthermore, the relative proportions of each cell type will require consideration, as will the specific neuronal cell type used. Indeed, recent work shows that in a complex culture environment there may be no requirement for growth factor supplementation 32 . In this study, iPSC-derived macrophages transferred to a neonatal brain further differentiated into microglia in a manner that relied solely on brain-specific cues 32 . These culture conditions are thus said to recapitulate the development and maturation of microglia in the brain, resulting in highly ramified cells expressing a number of microglial markers.
A recent study found that the transference of iPSC-derived human microglia into rat hippocampal co-cultures, transgenic mice modelling aspects of Alzheimer disease and human 3D brain organoids (containing neurons, astrocytes and oligodendrocytes) resulted in the production of cells with a more microglialike phenotype than was observed when the iPSC-derived microglia were cultured alone 30 . Furthermore, culturing iPSCderived microglia with factors such as CX 3 CL1, CD200 and transforming growth factor-β (TGFβ), which are typically produced by other brain cells (such as neurons and astrocytes) in the intact brain, produced cells with a transcriptome profile that was highly similar to that of human adult and fetal microglia and distinct from monocytes and blood dendritic cells 30 . The use of organoid cultures will also allow the influence of microglial risk factors on other cells in the brain, including radial glia and neurons, as well as the effects of macrophages on peripheral function to be examined 30, 52, 53 . This is important because microglia do not exist in isolation in the brain, and as previously mentioned, non-cell autonomous effects cannot be observed in 2D cultures of isolated cell types. Although each type of cell culture for investigating iPSC microglia and macrophage function (monoculture, co-culture or organoid) has its own advantages, each too comes with its own disadvantages, and these must be factored into models when interpreting results.
The future
There is little doubt that, over the next few years, we will see an increasing refinement in the protocols for the production of human iPSC-derived microglia, and hopefully, a consensus on the proteomic and genetic signatures of these cells (when compared with tissue-resident macrophages and adult primary microglia) will arise. The production of large numbers of macrophage-like and microglia-like cells from iPSCs is a major step towards understanding how human microglia and macrophages behave, given that the majority of published studies on microglia have used rodent cells. Furthermore, human iPSC-derived microglia hold promise for understanding the functional consequences of an increasing number of disease-associated risk factors linked to these cells 7 . This will be important for translational studies and drug screening and for the development of individualized gene therapy methodologies 54 . Future research directions could involve the use of human iPSC-generated microglia in transplantation therapies, as has been described for rodent models of such diseases as obsessive-compulsive disorder, CNS lysosomal storage diseases and Parkinson disease 55, 56 .
